1632 IPW



Robert Greene Sterne Foxerful, Kessler Jorge A, Goldstein Dardel, S. Comwell Robert W. Esmond 150 Gene G. Durkin Bidhele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcom Robert C. Millonig Lawrence B. Bugaisty Donald J. Featherstone Michael W. Messinger Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Jeffrey T. Helvey Heidi L. Kraus Albert L. Ferro* Donald R. Banowit Peter A. Jackman Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Banas J. Fel Buono Virgil Lee Beaston Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rae Lynn Prengaman George S. Bardmesser Daniel A. Kleimini Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller LuAnne M. DeSantis Ann E. Summerfield Tiera S. Coston Aric W. Ledford* Helene C. Carlson Timothy A. Doyle' Jessica L. Parezo Gaby L. Longsworth*

Lori A. Gordon'
Nicole D. Dretan'
Ted J. Ebersole
Jyoti C. Iyer'
Laura A. Vogel
Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Aaron L. Schwartz
Katina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford

Michelle K. Holoubek

Robert H. DeSelms Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse Michael G. Penn Christopher J. Walsh

Of Counsel Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

July 23, 2004

WRITER'S DIRECT NUMBER: (202) 772-8615 INTERNET ADDRESS: FRANKC@SKGF.COM

Art Unit 1632

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/052,817; Filed: January 23, 2002

For: Alpha-2-Macroglobulin Therapies and Drug Screening Methods for

Alzheimer's Disease

Inventors:

Tanzi et al.

Our Ref:

0609.4460005/TJS/FRC

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Second Supplemental Information Disclosure Statement;
- 2. Listing of the cited documents on Form PTO-1449 (1 sheet);
- 3. A copy of each of the two (2) cited documents on Form PTO-1449; and
- 4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents July 23, 2004 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Frank R. Cattighin

Frank R. Cottingham Attorney for Applicants Registration No. 50,437

FRC/pcd Encls.

290929v1

In re application of:

Tanzi et al.

Appl. No. 10/052,817

Filed: January 23, 2002

For: Alpha-2-Macroglobulin

> Therapies and Drug Screening Methods for Alzheimer's Disease

Confirmation No. 4182

Art Unit:

1632

Examiner:

Woitach, J.

Atty. Docket: 0609.4460005/TJS/FRC

Second Supplemental Information Disclosure Statement

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each document is provided.

The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed August 13, 2002, in connection with the above-captioned application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Frank R. Catty

Frank R. Cottingham Attorney for Applicants

Registration No. 50,437

Date: July 23, 2004

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

| Page 1 of 1 | | | | | | | | | |
|--|----------|------------|--|--------------------|--|----------------|-----------------------|-----------------|--|
| | | | (| 4 | TTY. DOCKET NO. 609.4460005/TJS/FRC | | ICATION NO. 52,817 | | |
| JANST NAMED INVENTOR | | | | | | | | | |
| \ DIEODIA | SECON | ID S | UPPLEMENTA COLORUPE STATE | ADMIN RY OF F | anzi et al. ILING DATE | ART | | | |
| January 23, 2002 1632 U.S. PATENT DOCUMENTS | | | | | | | | | |
| EXAMINER | <u> </u> | - 1 | | | | | | | |
| INITIAL | | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE | |
| | AA | \dashv | | | | | | | |
| • | AB AC | - | | | | | | | |
| | AD | | | | | | | | |
| | AE | | | | | | | | |
| | AF | | | | | | | | |
| | AG1 | | 5,508,167 | 04/16/1996 | Roses et al. | | | 04/13/1994 | |
| | AH | | | | | | | | |
| | AI | | | | | | | | |
| | AJ | | | | | | | | |
| | AK | | | | | | | <u></u> | |
| EXAMINER | Т | Т | ŀ | OREIGN PAT | TENT DOCUMENTS | | T | T | |
| INITIAL | AL | _ | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION Yes | |
| | AM | | | | | | | No Yes | |
| | AN | | | | | | | No Yes | |
| | AO | + | | | | | | No Yes No | |
| | AP | 1 | | | | | _ | Yes No | |
| | | L. | OTHER (Inc | ⊥ luding Author | , Title, Date, Pertinent Pages, | etc.) | | 1 | |
| | AR | | | | | | | | |
| | AS | 31 | Birkenmeier, G., and Stigbrand, T., "Production of conformation-specific monoclonal antibodies against α ₂ macroglobulin and their use for quantitation of total and transformed α ₂ macroglobulin in human blood," <i>J. Immunol. Meth. 162</i> :59-67, Elsevier Science (1993) | | | | | | |
| | AT | | | | | | | | |
| EXAMINER | <u></u> | <u>. I</u> | | | | DATE CC | NSIDERED | | |
| | | | | | ormance with MPEP 609. Draw line th | rough citation | n if not in confor | mance and not | |
| considered. Include copy of this form with next communication to Applicant. 290425_1.DOC | | | | | | | | | |